Medfirst Healthcare Services (ROCO:4175) Research & Development: NT$0 Mil (TTM As of Dec. 2025)


ROCO:4175 Medfirst Healthcare Services Inc ROCO:4175
71 GF Score
Price NT$53.20
GF Value NT$74.49
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Medfirst Healthcare Services Research & Development?

Medfirst Healthcare Services ROCO:4175 +0.19% 71 Research & Development is NT$0 Mil as of Dec. 2025. GuruFocus rates ROCO:4175 with a GF Score™ of 71/100 and a GF Value™ of NT$74.49 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medfirst Healthcare Services's Research & Development for the three months ended in Dec. 2025 was NT$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0 Mil.

Medfirst Healthcare Services  (ROCO:4175) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medfirst Healthcare Services Research & Development Related Terms

Medfirst Healthcare Services Research & Development Historical Data

* Premium members only.

The historical data trend for Medfirst Healthcare Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medfirst Healthcare Services Research & Development Chart

Medfirst Healthcare Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medfirst Healthcare Services Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4175
71GF Score
Medfirst Healthcare Services Inc ROCO:4175
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medfirst Healthcare Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$0 Mil mean?
Medfirst Healthcare Services (ROCO:4175) has a Research & Development of NT$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medfirst Healthcare Services and its competitors.
Is Medfirst Healthcare Services' Research & Development too high?
Medfirst Healthcare Services' current Research & Development is NT$0 Mil. Overall, Medfirst Healthcare Services has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medfirst Healthcare Services' Research & Development compare to competitors?
Medfirst Healthcare Services' Research & Development of NT$0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medfirst Healthcare Services and its competitors. Medfirst Healthcare Services's current Research & Development is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medfirst Healthcare Services stock overvalued right now?
Based on GuruFocus' analysis, Medfirst Healthcare Services (ROCO:4175) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$74.49, compared to a current price of NT$53.20 — trading 28.6% below its estimated fair value. The current Research & Development is NT$0 Mil. Medfirst Healthcare Services' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medfirst Healthcare Services (ROCO:4175), the current Research & Development is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medfirst Healthcare Services (ROCO:4175) Overvalued in 2026?

Based on GuruFocus' analysis, Medfirst Healthcare Services stock appears to be undervalued. The current stock price of NT$53.20 is trading 28.6% below its estimated GF Value™ of NT$74.49. GuruFocus considers Medfirst Healthcare Services to be Modestly Undervalued.

Key valuation signals for ROCO:4175:

  • Research & Development: NT$0 Mil
  • GF Value™: NT$74.49 vs. price of NT$53.20 (28.6% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4175 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medfirst Healthcare Services Business Description

Address No. 94, Fuxing 1st Road, 1st and 2nd Floor, Wenhua Village, Guishan district, Taoyuan, TWN, 333
Medfirst Healthcare Services Inc is mainly engaged in the sale of medical supplies and the management of shopping malls. The company's geographical segment includes Mainland China and Taiwan. It generates maximum revenue from Taiwan. The company derives a majority of its revenue from medical care products followed by health care.
71GF Score

Get the complete analysis for ROCO:4175

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$53.20
Price
NT$74.49
GF Value